TY - JOUR
T1 - Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT)
T2 - A multicentre, randomised, placebo-controlled trial
AU - Neuschwander-Tetri, Brent A.
AU - Loomba, Rohit
AU - Sanyal, Arun J.
AU - Lavine, Joel E.
AU - Van Natta, Mark L.
AU - Abdelmalek, Manal F.
AU - Chalasani, Naga
AU - Dasarathy, Srinivasan
AU - Diehl, Anna Mae
AU - Hameed, Bilal
AU - Kowdley, Kris V.
AU - McCullough, Arthur
AU - Terrault, Norah
AU - Clark, Jeanne M.
AU - Tonascia, James
AU - Brunt, Elizabeth M.
AU - Kleiner, David E.
AU - Doo, Edward
N1 - Funding Information:
The Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) is supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) ( grants U01DK061718, U01DK061728, U01DK061731, U01DK061732, U01DK061734, U01DK061737, U01DK061738, U01DK061730, U01DK061713 ). Several clinical centres had support from the National Center for Advancing Translational Sciences (NCATS) for NASH CRN Studies ( grants UL1TR000439, UL1TR000436, UL1TR000006, UL1TR000448, UL1TR000100, UL1TR000004, UL1TR000423, and UL1TR000058 ). Additional support was provided by the Laboratory of Pathology, Intramural Division of the National Cancer Institute. The NASH CRN expresses its gratitude to the patients enrolled in this study, Patricia Robuck for her guidance in trial design, Jay Hoofnagle for his guidance in trial design and data analysis, and Averell Sherker for his assistance in coordinating communications among the NIDDK, the industry sponsor, and the NASH CRN steering committee.
Funding Information:
BAN-T reports personal fees from Genentech/Roche, Nimbus Discovery, Boehringer Ingelheim, and Bristol-Myers Squibb. RL has research grants from Merck, Gilead, KineMed, Promedior, and Daiichi Sankyo, and has served as a consultant to Janssen, Merck, Gilead, Galmed, Siemens, and Genentech. AJS reports grants from Conatus, Gilead, Ikaria, Salix, Takeda, Astellas, Novartis, and Galectin; reports royalties from UpToDate; is a consulting advisor to Abbott, Genentech, Gilead, Ikaria, Merck, Norgine, Roche, Salix, Takeda, Nimbus, Nitto Denko, and Bristol-Myers Squibb; and is consultant with no financial conflicts for Genfit, Echosens, Immuron, Intercept, Novartis, Galectin, and Sequana. MFA reports grants from Gilead, Genfit, Immuron, Tobira, and Mochida, and consulting from Islet Sciences and TaiwanJ Pharmaceuticals. NC reports grants from Intercept, Gilead, Galectin, and Enterome and personal fees for consulting from Lilly, Merck, Aegerion, Boehringer Ingelheim, Janssen, Tobira, Mochida, AbbVie, Salix, and Nimbus. AMD reports grants from Shire, Metabolon, and Gilead and personal fees from AstraZeneca, Genentech, Japan Tobacco, and NuSI Foundation. KVK reports grants, personal fees, and non-financial support from BMS, Boehringer Ingelheim, Gilead, Janssen, Merck, Novartis, and Vertex; grants from Intercept and Mochida; personal fees and non-financial support from AbbVie; and personal fees from Evidera, Trio Health, and Tekmira. EB reports personal fees from Pfizer, Rottapharm, European Society of Pathology, and Synageva. All other authors declare no competing interests.
Publisher Copyright:
© 2015 Elsevier Ltd.
PY - 2015/3/14
Y1 - 2015/3/14
N2 - Background The bile acid derivative 6-ethylchenodeoxycholic acid (obeticholic acid) is a potent activator of the farnesoid X nuclear receptor that reduces liver fat and fibrosis in animal models of fatty liver disease. We assessed the efficacy of obeticholic acid in adult patients with non-alcoholic steatohepatitis. Methods We did a multicentre, double-blind, placebo-controlled, parallel group, randomised clinical trial at medical centres in the USA in patients with non-cirrhotic, non-alcoholic steatohepatitis to assess treatment with obeticholic acid given orally (25 mg daily) or placebo for 72 weeks. Patients were randomly assigned 1:1 using a computer-generated, centrally administered procedure, stratified by clinical centre and diabetes status. The primary outcome measure was improvement in centrally scored liver histology defined as a decrease in non-alcoholic fatty liver disease activity score by at least 2 points without worsening of fibrosis from baseline to the end of treatment. A planned interim analysis of change in alanine aminotransferase at 24 weeks undertaken before end-of-treatment (72 weeks) biopsies supported the decision to continue the trial (relative change in alanine aminotransferase -24%, 95% CI -45 to -3). A planned interim analysis of the primary outcome showed improved efficacy of obeticholic acid (p=0·0024) and supported a decision not to do end-of-treatment biopsies and end treatment early in 64 patients, but to continue the trial to obtain the 24-week post-treatment measures. Analyses were done by intention-to-treat. This trial was registered with ClinicalTrials.gov, number NCT01265498. Findings Between March 16, 2011, and Dec 3, 2012, 141 patients were randomly assigned to receive obeticholic acid and 142 to placebo. 50 (45%) of 110 patients in the obeticholic acid group who were meant to have biopsies at baseline and 72 weeks had improved liver histology compared with 23 (21%) of 109 such patients in the placebo group (relative risk 1·9, 95% CI 1·3 to 2·8; p=0·0002). 33 (23%) of 141 patients in the obeticholic acid developed pruritus compared with nine (6%) of 142 in the placebo group. Interpretation Obeticholic acid improved the histological features of non-alcoholic steatohepatitis, but its long-term benefits and safety need further clarification. Funding National Institute of Diabetes and Digestive and Kidney Diseases, Intercept Pharmaceuticals.
AB - Background The bile acid derivative 6-ethylchenodeoxycholic acid (obeticholic acid) is a potent activator of the farnesoid X nuclear receptor that reduces liver fat and fibrosis in animal models of fatty liver disease. We assessed the efficacy of obeticholic acid in adult patients with non-alcoholic steatohepatitis. Methods We did a multicentre, double-blind, placebo-controlled, parallel group, randomised clinical trial at medical centres in the USA in patients with non-cirrhotic, non-alcoholic steatohepatitis to assess treatment with obeticholic acid given orally (25 mg daily) or placebo for 72 weeks. Patients were randomly assigned 1:1 using a computer-generated, centrally administered procedure, stratified by clinical centre and diabetes status. The primary outcome measure was improvement in centrally scored liver histology defined as a decrease in non-alcoholic fatty liver disease activity score by at least 2 points without worsening of fibrosis from baseline to the end of treatment. A planned interim analysis of change in alanine aminotransferase at 24 weeks undertaken before end-of-treatment (72 weeks) biopsies supported the decision to continue the trial (relative change in alanine aminotransferase -24%, 95% CI -45 to -3). A planned interim analysis of the primary outcome showed improved efficacy of obeticholic acid (p=0·0024) and supported a decision not to do end-of-treatment biopsies and end treatment early in 64 patients, but to continue the trial to obtain the 24-week post-treatment measures. Analyses were done by intention-to-treat. This trial was registered with ClinicalTrials.gov, number NCT01265498. Findings Between March 16, 2011, and Dec 3, 2012, 141 patients were randomly assigned to receive obeticholic acid and 142 to placebo. 50 (45%) of 110 patients in the obeticholic acid group who were meant to have biopsies at baseline and 72 weeks had improved liver histology compared with 23 (21%) of 109 such patients in the placebo group (relative risk 1·9, 95% CI 1·3 to 2·8; p=0·0002). 33 (23%) of 141 patients in the obeticholic acid developed pruritus compared with nine (6%) of 142 in the placebo group. Interpretation Obeticholic acid improved the histological features of non-alcoholic steatohepatitis, but its long-term benefits and safety need further clarification. Funding National Institute of Diabetes and Digestive and Kidney Diseases, Intercept Pharmaceuticals.
UR - http://www.scopus.com/inward/record.url?scp=84929266699&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84929266699&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(14)61933-4
DO - 10.1016/S0140-6736(14)61933-4
M3 - Article
C2 - 25468160
AN - SCOPUS:84929266699
VL - 385
SP - 956
EP - 965
JO - The Lancet
JF - The Lancet
SN - 0140-6736
IS - 9972
ER -